Skip to main content
OpenTrials

Clinical trial condition

Haemophilus Influenzae Type b

Explore clinical trials studying Haemophilus Influenzae Type b. Study availability and eligibility vary by location and protocol.

84 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Haemophilus Influenzae Type b trial results

Completed

Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine

NCT00327184

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Espoo, Finland
  • GSK Investigational Site Helsinki, Finland
  • GSK Investigational Site Helsinki, Finland
  • GSK Investigational Site Jarvenpaa, Finland
View all 16 locations
View Trial Details
Completed

Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488

NCT00307567

Conditions
Acellular Pertussis, Actinomycetales Infections, Bacterial Infections, +32 more
Locations
  • GSK Investigational Site Bad Saulgau, Baden-Wurttemberg, Germany
  • GSK Investigational Site Bretten, Baden-Wurttemberg, Germany
  • GSK Investigational Site Eppelheim, Baden-Wurttemberg, Germany
  • GSK Investigational Site Kehl, Baden-Wurttemberg, Germany
View all 51 locations
View Trial Details
Completed

Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine

NCT00258700

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Bydgoszcz, Poland
  • GSK Investigational Site Gdansk, Poland
  • GSK Investigational Site Kielce, Poland
  • GSK Investigational Site Krakow, Poland
View Trial Details
Completed

Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197

NCT00263653

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Almería, Spain
  • GSK Investigational Site Almería, Spain
  • GSK Investigational Site Antequera/Málaga, Spain
  • GSK Investigational Site Aravaca, Spain
View all 16 locations
View Trial Details
Completed

Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants

NCT00290303

Conditions
Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +21 more
Locations
  • GSK Investigational Site Manila, Philippines
  • GSK Investigational Site Quezon City, Philippines
  • GSK Investigational Site Sampaloc, Manila, Philippines
View Trial Details
Completed

Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects

NCT00323050

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Alcorcón, Spain
  • GSK Investigational Site Almeira, Spain
  • GSK Investigational Site Barcelona, Spain
  • GSK Investigational Site Barcelona, Spain
View all 16 locations
View Trial Details

Related conditions